Literature DB >> 28818868

Erythropoietin stimulates murine and human fibroblast growth factor-23, revealing novel roles for bone and bone marrow.

Erica L Clinkenbeard1, Mark R Hanudel2, Keith R Stayrook3, Hitesh Nidumanda Appaiah1, Emily G Farrow4, Taryn A Cass1, Lelia J Summers1, Colin S Ip1, Julia M Hum1, Joseph C Thomas1, Mircea Ivan5, Briana M Richine6, Rebecca J Chan6, Thomas L Clemens7, Ernestina Schipani8, Yves Sabbagh9, Linlin Xu10, Edward F Srour6, Marta B Alvarez11, Melissa A Kacena11, Isidro B Salusky2, Tomas Ganz12, Elizabeta Nemeth12, Kenneth E White13.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28818868      PMCID: PMC5664401          DOI: 10.3324/haematol.2017.167882

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   11.047


× No keyword cloud information.
  13 in total

1.  FGF23 induces left ventricular hypertrophy.

Authors:  Christian Faul; Ansel P Amaral; Behzad Oskouei; Ming-Chang Hu; Alexis Sloan; Tamara Isakova; Orlando M Gutiérrez; Robier Aguillon-Prada; Joy Lincoln; Joshua M Hare; Peter Mundel; Azorides Morales; Julia Scialla; Michael Fischer; Elsayed Z Soliman; Jing Chen; Alan S Go; Sylvia E Rosas; Lisa Nessel; Raymond R Townsend; Harold I Feldman; Martin St John Sutton; Akinlolu Ojo; Crystal Gadegbeku; Giovana Seno Di Marco; Stefan Reuter; Dominik Kentrup; Klaus Tiemann; Marcus Brand; Joseph A Hill; Orson W Moe; Makoto Kuro-O; John W Kusek; Martin G Keane; Myles Wolf
Journal:  J Clin Invest       Date:  2011-10-10       Impact factor: 14.808

2.  Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice.

Authors:  Mark R Hanudel; Kristine Chua; Maxime Rappaport; Victoria Gabayan; Erika Valore; David Goltzman; Tomas Ganz; Elizabeta Nemeth; Isidro B Salusky
Journal:  Am J Physiol Renal Physiol       Date:  2016-10-12

3.  Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.

Authors:  Tamara Isakova; Huiliang Xie; Wei Yang; Dawei Xie; Amanda Hyre Anderson; Julia Scialla; Patricia Wahl; Orlando M Gutiérrez; Susan Steigerwalt; Jiang He; Stanley Schwartz; Joan Lo; Akinlolu Ojo; James Sondheimer; Chi-yuan Hsu; James Lash; Mary Leonard; John W Kusek; Harold I Feldman; Myles Wolf
Journal:  JAMA       Date:  2011-06-15       Impact factor: 56.272

4.  FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis.

Authors:  Lindsay M Coe; Sangeetha Vadakke Madathil; Carla Casu; Beate Lanske; Stefano Rivella; Despina Sitara
Journal:  J Biol Chem       Date:  2014-02-07       Impact factor: 5.157

5.  Suppression of hepcidin during anemia requires erythropoietic activity.

Authors:  Mihwa Pak; Miguel A Lopez; Victroia Gabayan; Tomas Ganz; Seth Rivera
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

6.  Impact of interactions of cellular components of the bone marrow microenvironment on hematopoietic stem and progenitor cell function.

Authors:  Brahmananda R Chitteti; Ying-Hua Cheng; Bradley Poteat; Sonia Rodriguez-Rodriguez; W Scott Goebel; Nadia Carlesso; Melissa A Kacena; Edward F Srour
Journal:  Blood       Date:  2010-02-12       Impact factor: 22.113

7.  Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy.

Authors:  Yves Sabbagh; Fabiana Giorgeti Graciolli; Stephen O'Brien; Wen Tang; Luciene Machado dos Reis; Susan Ryan; Lucy Phillips; Joseph Boulanger; Wenping Song; Christina Bracken; Shiguang Liu; Steven Ledbetter; Paul Dechow; Maria Eugenia F Canziani; Aluizio B Carvalho; Vanda Jorgetti; Rosa M A Moyses; Susan C Schiavi
Journal:  J Bone Miner Res       Date:  2012-08       Impact factor: 6.741

8.  Neonatal iron deficiency causes abnormal phosphate metabolism by elevating FGF23 in normal and ADHR mice.

Authors:  Erica L Clinkenbeard; Emily G Farrow; Lelia J Summers; Taryn A Cass; Jessica L Roberts; Christine A Bayt; Tim Lahm; Marjorie Albrecht; Matthew R Allen; Munro Peacock; Kenneth E White
Journal:  J Bone Miner Res       Date:  2014-02       Impact factor: 6.741

9.  Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study.

Authors:  Danilo Fliser; Barbara Kollerits; Ulrich Neyer; Donna P Ankerst; Karl Lhotta; Arno Lingenhel; Eberhard Ritz; Florian Kronenberg; Erich Kuen; Paul König; Günter Kraatz; Johannes F E Mann; Gerhard A Müller; Hans Köhler; Peter Riegler
Journal:  J Am Soc Nephrol       Date:  2007-07-26       Impact factor: 10.121

10.  Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease.

Authors:  Peter A McCullough; Huiman X Barnhart; Jula K Inrig; Donal Reddan; Shelly Sapp; Uptal D Patel; Ajay K Singh; Lynda A Szczech; Robert M Califf
Journal:  Am J Nephrol       Date:  2013-05-25       Impact factor: 3.754

View more
  48 in total

Review 1.  When Low Bone Mineral Density and Fractures Is Not Osteoporosis.

Authors:  Smita Jha; Marquis Chapman; Kelly Roszko
Journal:  Curr Osteoporos Rep       Date:  2019-10       Impact factor: 5.096

Review 2.  Tumor-Induced Osteomalacia.

Authors:  Pablo Florenzano; Iris R Hartley; Macarena Jimenez; Kelly Roszko; Rachel I Gafni; Michael T Collins
Journal:  Calcif Tissue Int       Date:  2020-06-05       Impact factor: 4.333

Review 3.  Crosstalk between fibroblast growth factor 23, iron, erythropoietin, and inflammation in kidney disease.

Authors:  Jodie L Babitt; Despina Sitara
Journal:  Curr Opin Nephrol Hypertens       Date:  2019-07       Impact factor: 2.894

Review 4.  Erythropoiesis, EPO, macrophages, and bone.

Authors:  Joshua T Eggold; Erinn B Rankin
Journal:  Bone       Date:  2018-03-15       Impact factor: 4.398

Review 5.  Non-renal-Related Mechanisms of FGF23 Pathophysiology.

Authors:  Mark R Hanudel; Marciana Laster; Isidro B Salusky
Journal:  Curr Osteoporos Rep       Date:  2018-12       Impact factor: 5.096

Review 6.  Fibroblast growth factor 23 and α-Klotho co-dependent and independent functions.

Authors:  L Darryl Quarles
Journal:  Curr Opin Nephrol Hypertens       Date:  2019-01       Impact factor: 2.894

7.  Effects of erythropoietin on fibroblast growth factor 23 in mice and humans.

Authors:  Mark R Hanudel; Michele F Eisenga; Maxime Rappaport; Kristine Chua; Bo Qiao; Grace Jung; Victoria Gabayan; Barbara Gales; Georgina Ramos; Maarten A de Jong; Jelmer J van Zanden; Martin H de Borst; Stephan J L Bakker; Elizabeta Nemeth; Isidro B Salusky; Carlo A J M Gaillard; Tomas Ganz
Journal:  Nephrol Dial Transplant       Date:  2019-12-01       Impact factor: 5.992

8.  Extra-Large Gα Protein (XLαs) Deficiency Causes Severe Adenine-Induced Renal Injury with Massive FGF23 Elevation.

Authors:  Julia Matthias; Qiuxia Cui; Lauren T Shumate; Antonius Plagge; Qing He; Murat Bastepe
Journal:  Endocrinology       Date:  2020-01-01       Impact factor: 4.736

9.  Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease.

Authors:  Connor Francis; Guillaume Courbon; Claire Gerber; Samantha Neuburg; Xueyan Wang; Corey Dussold; Maralee Capella; Lixin Qi; Tamara Isakova; Rupal Mehta; Aline Martin; Myles Wolf; Valentin David
Journal:  Kidney Int       Date:  2019-08-30       Impact factor: 10.612

10.  Erythropoietin stimulates fibroblast growth factor 23 (FGF23) in mice and men.

Authors:  Arezoo Daryadel; Carla Bettoni; Thomas Haider; Pedro H Imenez Silva; Udo Schnitzbauer; Eva Maria Pastor-Arroyo; Roland H Wenger; Max Gassmann; Carsten A Wagner
Journal:  Pflugers Arch       Date:  2018-07-02       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.